الفهرس 
M ANAGEMENT OF HCV PATIENTSOnly 14 pages are availabe for public view
 |  | from | 114 |  |  |
| | | from | 114 | | |
Abstract
HCV infection is a major cause of liver cirrhosis, (HCC) and end-stage liver disease. The development of an interferon-free, all-oral treatment regimen represents an important advance. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analogue HCV NS5B polymerase inhibitor) with or without Ribavirin in chronic HCV patients.
Results
Sustained virological response (12 weeks ) after end of the treatment in more than 90% of patients , Liver function parameters including albumin, bilirubin, and prothrombin time and liver enzymes Ast , Alt improved in the majority of patients during and after the end of therapy ,but there is significant increase in urea level , serum creatinin and HbA1C.
There is significant decrease in LDL and mild increase in TG level.
Conclusion
Once-daily oral daclatasvir plus sofosbuvir with or without Ribavirin was associated with high rates of sustained virologic response among patients infected with HCV , including chronic cirrhotic patients and relapsers , successful treatment associated with Improvement of liver function parameters in the majority of patients , Increase in urea level, serum creatinin and HbA1C.
There is significant decrease in LDL and mild increase in TG level.
Recommendations
• To avoid side effects of DAAs on patients, they have to restrict diet and continue medical treatment of diabetes with follow up RBS.
• During treatment, patient must follow up renal function to avoid the side effects of drug.
• Good monitoring for hyperlipidemia to avoid ischemic heart disease.